Compare Adobe Systems Inc (ADBE) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Amphastar Pharmaceuticals Inc — how do they compare? Adobe Systems Inc trades at $263 (market cap $108.50B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Adobe Systems Inc is far larger — about 125.6× Amphastar Pharmaceuticals Inc's market cap, and Adobe Systems Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | AMPH | |
|---|---|---|
Market Cap | $108.50B | $863.95M |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $30.81 |
52-Week Low | $193.41 | $16.87 |
Enterprise Value | $109.94B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $5.96 exceeding the $5.82 estimate. Revenue grew to $23.77B in 2025, and net income margin improved to 28.69%. However, the stock faces headwinds from AI competition fears and a recent 52-week low, as noted by Citi on April 10, 2026.
The outlook is mixed: robust fundamentals and a 49.2% buy rating from analysts support upside potential, with a consensus price target of $248.86. Key risks include generative AI disruption and CEO transition uncertainty. Investors should weigh strong cash flows against competitive pressures in the software sector.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
